UNH vs VKTX

UnitedHealth Group (UNH) remains a robust, high-quality mega-cap in the mature and highly regulated healthcare sector. Q1 2026 adjusted EPS of $7.23, a recent dividend increase to $2.32, and some analyst upgrades (e.g., Truist to $440, Goldman Sachs Conviction Buy) reflect solid operational performance and financial strength. However, these are characteristics of a stable compounder, not a company...

Viking Therapeutics maintains strong 10x growth potential, with its lead asset VK2735 (a dual GLP-1/GIP agonist) continuing to show compelling clinical promise in the lucrative metabolic disorder market. Recent additional positive Phase 2 data for the oral formulation, showing up to 12.2% weight loss, reinforces its potential as a best-in-class option and strengthens its competitive position. Whil...